Navigation Links
New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role
Date:2/12/2009

Alzheimer's disease

Two thirds of all patients with dementia suffer from Alzheimer's disease. Estimates indicate that by 2010 our country will have more than 150,000 Alzheimer's patients. Alzheimer's is a disease that gradually destroys brain cells, with the result that the mental capacity of patients with Alzheimer's gradually declines. At first, memory begins to fail, but the patient's cognitive capabilities also deteriorate as the disease progresses. Today, this disease cannot yet be cured. Current medicines for Alzheimer's patients sustain the memory functions for a short time, but they are unable to stop the brain cells from dying off. At best, they are able to limit the loss of memory during the early phases of the disease.

The β-amyloid cascade

The brains of Alzheimer's patients typically show the presence of amyloid plaques, which are abnormal accumulations of a protein (β-amyloid) between the neurons. The sticky β-amyloid develops when the precursor protein (amyloid precursor protein or APP) is cut into pieces incorrectly.

GPR3: target for new medicine

Several years ago, Bart De Strooper and other researchers elucidated the way in which these plaques originate and discovered that secretases play a large role in this process. Now, under the direction of Bart De Strooper, and in collaboration with researchers from the biotech company Galapagos, Amantha Thathiah and her colleagues have investigated whether additional substances are also involved in the development of the plaques. Which is apparently the case: Galapagos has identified the GPR3 protein as a new player. The VIB researchers have been able to show − in vitro (in cells isolated and studied in the laboratory) as well as in vivo (in living animals − mice, in this instance) − that blocking GPR3 leads to reduction of the plaques.

Importance of this research

The GPR3 protein is an important targe
'/>"/>

Contact: Pieter Van Dooren
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New target for anti-flu drug development
3. Central targets may hinder wider waste management objectives
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UIC researchers find promising new targets for antibiotics
6. Targeting nerve growth factor may cure liver cancer
7. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
8. Linchpin gene may be useful target for new breast cancer therapies
9. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
10. Study reveals a key to blood vessel growth and possible drug target
11. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... one day in the distant future, miniature, medically-savvy computers ... them on the spot by releasing a suitable drug, ... reality, computers must be sufficiently small to fit into ... to various cellular systems. These challenges can be best ...
... HOLE, MASS. -- Among the animals that are appealing ... to mind. Slender, limbless, primitive blobs that look pretty ... boring. I wouldn,t recommend them for a home aquarium," ... Biological Laboratory (MBL). Yet Nasi and his collaborators managed ...
... Darwin on the Galapagos Islands, researchers have been interested ... particular island, can lead to the formation of new ... selection is a process whereby heritable traits that enhance ... heritable traits become less common. Over time, animals and ...
Cached Biology News:A genetic device performs DNA diagnosis 2Sensing the light, but not to see 2LSU professor discovers how new corals species form in the ocean 2LSU professor discovers how new corals species form in the ocean 3
(Date:3/5/2015)... 2015  In response to the incorrect assertions by ... on February 12, 2015. Impeto Medical SAS ... health and their SUDOSCAN® devices have been proven to ... prefers to have the courts decide this dispute rather ... 40 articles written by Key Opinion Leaders, published by ...
(Date:3/4/2015)... Nev. , March 4, 2015 PDL BioPharma, Inc. ... adjusted conversion rate for the: , 3.75% Convertible ... 174.8506 shares of common stock per $1,000 principal amount or ... The conversion rate for the note is adjusted in connection ... on March 12, 2015, to all stockholders who own shares of ...
(Date:3/4/2015)... USDM Life Sciences , a leading ... hired David Blewitt as Vice President of ... and Solutions at USDM Life Sciences , which help ... compliance with government regulations worldwide. , For more ... sciences regulatory and IS compliance professional with extensive hands-on ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
Breaking Biology Technology:Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... Focus on ... Supportive ... Companies, Inc. (NYSE: PRX ) today announced its commitment,to ... of Strativa Pharmaceuticals, its proprietary,specialty pharmaceuticals division. Strativa Pharmaceuticals will ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ), a ... of drugs for the treatment of human ... part of the,restructuring, Idenix has amended the ... Tyzeka(R)/Sebivo(R). Per the amended agreement, Idenix,will discontinue ...
... Settlement, NORCROSS, Ga., Sept. 28 ... leader in providing automated instrument-reagent,systems to the ... and Exchange Commission (SEC) has agreed to ... certain,activities involving the company,s Italian subsidiary. ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
Direct ELISA Assay Diluent, 100 mL...
Assay Diluent Trial Pack, 4 x 100 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
...
Biology Products: